ClinicalTrials.gg
Not yet recruitingNCT07122778Carpe DIEMUpdated Aug 14, 2025

Impact of Diet-induced Change in Energy Balance on Metabolism in Endurance Athletes

An interventional study of Controlled energy-deficit diet and Habitual diet with surplus snacks in Energy Balance, Energy Deficit and Low Energy Availability, sponsored by University of Bath. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by University of Bath · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Study summary

Recent research has suggested that increasing levels of physical activity are associated with a reduction in the independent components that contribute to total energy expenditure (such as resting metabolic rate and non-exercise movement) - this occurs to conserve energy required for physical activity where energy provision becomes scarce. There are potential deleterious health and performance consequences of a reduced energy supply to fundamental metabolic processes, putting individuals regularly undertaking high levels of physical activity, such as endurance athletes, at risk. However, this association is largely based on observational data in only moderately active populations, and it is currently unclear what role energy balance status and biological sex has on this relationship.

This research intends to address these unknowns by assessing the impact of diet-induced manipulation of energy balance (conditions of energy deficit and energy surplus) in individuals undertaking habitually high levels of physical activity on independent components of total energy expenditure (resting metabolism, exercise and non-exercise movement).

Male and female athletes conducting regular moderate-to-high training volumes will undertake a randomised crossover study with a 7-day state of energy deficit and a 7-day state of energy surplus. Participants will continue to live and train as normal, but their diet will be controlled by specific food provision over the intervention periods in order to facilitate both conditions. Independent components of energy expenditure, markers of health, metabolism and performance will be measured to allow for comparison of conditions.

Read the detailed description

People with very active lifestyles such as athletes, dancers, and military personnel, need to eat a lot of food to make up for the large amount of energy they burn. If they don't match their food intake to their energy needs, they may enter a state of 'energy deficit'. This means their bodies are burning more calories than they're taking in, which can lower performance, increase the risk of injuries and illnesses, and potentially harm overall health.

Traditional scientific understanding assumes that more doing physically activity leads to burning more calories (the 'additive' model). However, newer studies suggest that the body might have built-in safeguards to limit how many total calories it burns, no matter how much a person exercises. This idea (the 'constrained' model) proposes that when people exercise more, their bodies might compensate by slowing down other metabolic processes to keep overall energy use within a certain range. Although this mechanism could help the body conserve energy, it may also mean that essential functions (like immune system support and reproductive function) can become impaired.

Most research on energy deficit so far has focused on people with normal or moderate levels of physical activity. Because extremely active people experience far higher daily energy demands, the 'constrained' mechanisms could manifest differently or to a greater degree and the negative health and performance consequences might be more severe. There is also limited knowledge about how quickly these changes in energy use begin and how they affect important processes at the cellular level, such as muscle mitochondrial function or immune cell health.

This study aims to fill these gaps by measuring total energy use (and its separate parts) in highly active individuals under two conditions: when participants eat enough to cover their energy demands and when participants are purposely in an energy deficit (intentionally eating less than they need). One of our main goals is to measure changes in resting metabolic rate (RMR), which is the energy the body uses at rest to keep vital functions going. Investigators will also examine cellular changes by looking at indicators like immune cell function to see how these might help us detect early signs of harmful energy shortages.

By understanding whether, and to what extent, the body's energy use is 'constrained', investigators can develop better guidelines to help very active individuals avoid unhealthy energy deficits. Ultimately, this research could improve both performance and long-term health for athletes, military personnel, dancers, and anyone else who regularly exercises at high levels.

02

Conditions studied

  • Energy Balance
  • Energy Deficit
  • Low Energy Availability
  • Relative Energy Deficiency in Sport

Keywords

  • energy deficit
  • energy balance
  • energy availability
  • physical activity
03

In context

Relative Energy Deficiency in Sport

20 studies on the registry are indexed under Relative Energy Deficiency in Sport; 9 are open to participants now.

This study's planned enrollment of 20 is below the median of 28 across 10 interventional studies indexed under Relative Energy Deficiency in Sport.

Browse Relative Energy Deficiency in Sport studies →

Lead sponsor

University of Bath is the lead sponsor of 94 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Self-identified endurance-trained sport participants
  • Training volume: >7 hours per week endurance training
  • Training frequency: at least 5 days per week

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of Relative Energy Deficiency in Sport (REDs)
  • Active eating disorder (EDE-Q)
  • Active flare of a chronic disease (e.g. inflammatory bowel disease)
  • Type 1 or 2 diabetes mellitus
  • Untreated or undergoing active treatment of anaemia (any cause)
  • Current injury which precludes undertaking high volume endurance training
  • Individuals following a habitual low-carbohydrate, high-fat diet
  • Any medical diagnosis which precludes intense exercise (e.g. untreated cardiac arrhythmia)
  • Allergy or intolerance to study foods
  • Blood donation within preceding 8 weeks of study start date
  • Use of medications that affect substrate utilisation (e.g. statins, , thyroxine, HRT)
  • For females: current pregnancy, breastfeeding within past 6 months or
  • Unable to undertake a treadmill running test
  • Participation in any research study in the past 8 weeks
  • Participation in a research study within the past year involving more than one DEXA scan
  • Unable to provide due to impaired cognitive capacity or decision-making ability
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Energy deficit

    Diet-induced 50% energy deficit (based on estimated average total daily energy expenditure) by allocation of pre-made meals and snacks over 7-days

    Dietary Supplement: Controlled energy-deficit diet

  • Experimental
    Energy surplus

    Diet-induced energy surplus (approximately 500-1000kcal/day) achieved by allocation of additional snacks to be consumed on top of habitual free-living diet, to avoid inadvertent energy deficit

    Dietary Supplement: Habitual diet with surplus snacks

Interventions

  • Dietary supplementControlled energy-deficit diet

    Participants receive a prepared diet providing approximately 50% of their estimated daily energy expenditure to induce a sustained energy deficit

    Also known as: Energy deficit

  • Dietary supplementHabitual diet with surplus snacks

    Participants continue their normal diet with the addition of high-calorie snack items to achieve an approximate daily energy surplus

    Also known as: Energy surplus

06

What researchers measure

Primary outcomes

  1. Resting metabolic rate (RMR) in kcal/day

    The effect of a 7-day period of energy expenditure-matched diet-induced energy deficit versus energy surplus on RMR. Measured via indirect calorimetry using the Douglas bag method. Expired gas will be collected in a seated, fasted state under thermoneutral conditions, and oxygen consumption and carbon dioxide production will be used to calculate energy expenditure.

    Time frame: Measured at lab visits 1-5 (baseline and pre- and post-interventions) from 0 to 12 weeks.

Secondary outcomes

  1. Total energy expenditure (from doubly labelled water) in kcal/day

    Time frame: Measured during both 7-day interventions starting at approximately week 4 and week 9.

  2. Total energy expenditure ( from sum of independent components of energy expenditure) in kcal/day

    Time frame: Measured during both 7-day interventions starting at approximately week 4 and week 9

  3. Peripheral blood mononuclear cell (PBMC) mitochondrial respiration

    Assessment of mitochondrial respiratory function in isolated PBMCs using high-resolution respirometry (Oroboros). Measures include basal (routine), leak, oxidative phosphorylation (OXPHOS), and electron transfer system (ETS) capacity states. Data will be used to assess changes in mitochondrial function in response to exercise and nutritional intervention. Units: pmol O₂·s-¹·10⁶ cells-¹ (picomoles of oxygen consumed per second per million PBMCs).

    Time frame: Measured pre- and post-exercise at visits 2/3 (pre- and post-intervention 1) and visits 4/5 (pre- and post-intervention 2), approximately weeks 4-12.

  4. Sub-maximal exercise performance (during steady-state treadmill exercise)

    Running economy (oxygen consumption at a fixed submaximal speed, expressed as ml O₂·kg-¹·min-¹)

    Time frame: Measured at lab visits 1-5 (baseline and pre- and post-interventions) from 0 to 12 weeks.

  5. Free T3 in pmol/L

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks.

  6. Interstitial glucose concentration in mmol/l

    Continuous glucose monitoring using Dexcom G7 reporting mean daily and daily variability in interstitial glucose concentration.

    Time frame: Measured during both 7-day interventions starting at approximately week 4 and week 9.

  7. Bone mineral density (DEXA)

    Bone mineral density will be assessed using dual-energy X-ray absorptiometry (DEXA). DEXA will provide areal BMD (g/cm²).

    Time frame: Measured at lab visits 1-5 (baseline and pre- and post-interventions) from 0 to 12 weeks.

  8. Bone mineral density (pQCT)

    Bone mineral density will be assessed using peripheral quantitative computed tomography (pQCT) at the tibia. Measures will include volumetric BMD (vBMD) in mg/cm³ in cortical and trabecular compartments.

    Time frame: Measured at lab visits 1-5 (baseline and pre- and post-interventions) from 0 to 12 weeks.

  9. Subjective measures of fatigue

    Daily subjective fatigue will be assessed using the Hooper Index (fatigue subscale, 5-item 1-5 Likert scale). Higher scores indicate greater perceived fatigue. Units: Hooper Index: total score (5-25)

    Time frame: Measured at lab visits 1-5 (baseline and pre- and post-interventions) from 0 to 12 weeks.

  10. Sleep duration in h/night

    Accelerometer-dervied using arm-worn Actigraph LEAP device.

    Time frame: Measured during both 7-day interventions starting at approximately week 4 and week 9.

  11. Non-exercise activity thermogenesis (NEAT) (estimated from ActiGraph LEAP device) in kcal/day

    Time frame: Measured during both 7-day interventions starting at approximately week 4 and week 9

  12. Exercise energy expenditure (estimated from ActiGraph LEAP device) in kcal/day

    Time frame: Measured during both 7-day interventions starting at approximately week 4 and week 9

  13. Sub-maximal exercise performance (during steady-state treadmill exercise)

    Substrate utilisation (absolute in g·min-¹)

    Time frame: Measured at lab visits 1-5 (baseline and pre- and post-interventions) from 0 to 12 weeks

  14. Sub-maximal exercise performance (during steady-state treadmill exercise)

    Substrate utilisation (relative as % total energy expenditure)

    Time frame: Measured at lab visits 1-5 (baseline and pre- and post-interventions) from 0 to 12 weeks

  15. Bone mineral density (pQCT)

    Cross-sectional area in mm²

    Time frame: Measured at lab visits 1-5 (baseline and pre- and post-interventions) from 0 to 12 weeks

  16. Bone mineral density (pQCT)

    Strength-strain index in mm³

    Time frame: Measured at lab visits 1-5 (baseline and pre- and post-interventions) from 0 to 12 weeks

  17. Subjective measures of fatigue

    Daily subjective fatigue will be assessed using the Fatigue Assessment Scale (FAS), a 10-item validated questionnaire scored from 10 to 50. Higher scores indicate greater perceived fatigue. Units: total score (10-50).

    Time frame: Measured at lab visits 1-5 (baseline and pre- and post-interventions) from 0 to 12 weeks.

  18. Total testosterone in nmol/L

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  19. Free testosterone in pg/mL

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  20. cortisol in nmol/L

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  21. IGF-1 in ng/mL

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  22. leptin in ng/mL

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  23. Female-specific hormones: oestradiol in pmol/L

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  24. Female-specific hormones: FSH in IU/L

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  25. Female-specific hormones: LH in IU/L

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  26. Inflammatory markers: interleukin-6 (IL-6) in pg/mL

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  27. high-sensitivity C-reactive protein (hsCRP) in mg/L

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  28. ferritin in µg/L

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  29. serum iron in µmol/L

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  30. transferrin in g/L

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  31. total iron binding capacity (TIBC) in µmol/L

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  32. transferrin saturation as a percentage

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  33. soluble transferrin receptor in mg/L

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  34. hepcidin in ng/mL

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  35. Lipid markers: total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides in mmol/L; non-esterified fatty acids (NEFA) in mmol/L; and glycerol in µmol/L.

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

  36. HbA1c will be reported in both % (DCCT-aligned) and mmol/mol (IFCC standard).

    Time frame: Measured at lab visits 2-5 (pre- and post-interventions) from 4 to 12 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Aug 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
Aug 14, 2025
StartEst.
Aug 2025
Primary completionEst.
Aug 2026
CompletionEst.
May 2027
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07122778
Lead sponsor
University of Bath
Collaborators
Royal Centre for Defence Medicine
Responsible party
Josh Bakker-Dyos (Principal Investigator, University of Bath) — Principal investigator
First posted
Aug 14, 2025
Start date
Aug 2025 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Aug 14, 2025

Study contacts

Joshua J Bakker-Dyos, BSc(Hons) MBChB
Contact
jbd28@bath.ac.uk
+447740191473

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion